# PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT06244992** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pyrotech Therapeutics, Inc.** · enrollment: 68 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** PTT-936
- **DRUG:** Combination of PTT-936 and anti-PD-1/L1 therapy

## Key facts

- **NCT ID:** NCT06244992
- **Lead sponsor:** Pyrotech Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244992, "PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06244992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*